科研之友
微信
新浪微博
Facebook
分享链接
摘要
To evaluate the impact of human immunodeficiency virus (HIV) co-infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) on the efficacy of highly active anti-retroviral therapy (HARRT) and analysis on the variable pattern of resistant's sites in HIV RNA. The patients were divided into three groups: HIV/HBV/HCV co-infection group (23 patients), HIV/HCV co-infection group (168 patients), and HIV-only group (178 patients). All patients in the 3 groups were given the same HAART, that was, AZT+DDI+NVP, but not given other antivirus treatment including HCV and HBV antivirus therapy. HIV RNA, HCV RNA or HBV DNA were detected by real time PCR every 90 days, meanwhile the counts of CD(4)(+) T lymphocyte and liver function including ALT(alanine transaminase), AST (aspartate aminotransferase), and total bilirubin (T-Bil) were tested. According to the titer of HIV RNA(>10(4)copies/ml) in sera during the one year HAART, polymerase genes of HIV RNA were sequenced and analyzed. During one-year HAART, HIV RNA of HIV-only group, HIV/HBV/HCV co-infection group and HIV/HCV co-infection group decreased significantly from 6.78 +/- 1.08, 6.23 +/- 1.34, 6.54 +/- 1.23 log copies/ml to 0.53 +/- 0.15, 0.67 +/- 0.16, 0.43 +/- 0.11 log copies/ml respectively (P-Value < 0.001). And CD(4)(+) Tlymphocyte counts of the three groups elevated significantly from 197 +/- 127, 184 +/- 113, 213 +/- 143 cells/mu l to 382 +/- 74, 383 +/- 70, 378 +/- 76 cells/mu l respectively (P-value<0.001). However there were no differences among the three groups in HIV RNA and CD(4)(+) T cell counts. There were no differences in liver functions including ALT, AST and T-Bil among the three groups. The detection of sites of drug resistance: the major mutant sites to AZT+DDI were at M41L, E44A, K70KR, D67N, L210W, T215Y or K219W which were highly resistant and to NVP were at A98G, V179H, Y181C,K103N or G190A which were highly resistant in the 3 groups. Meanwhile, the rates resistant of emergence were similar and there were no sites to 3TC and protease inhibitors (PIs) in the above HAART groups. HIV co-infected with HBV and/or HCV does not impact on the efficacy of HAART. What more, HAART does not impact HCV replication.
[ZHAO Jie, YU Zu-jiang, KAN Quan-cheng, LI Xiao-fei, LI Zhi-qin, LIANG Hong-xia. A retrospective study: The Influence of human immunodeficiency virus co-infection with hepatitis C virus or hepatitis B virus on the efficacy with HAART in China AIDS area. Life Science Journal. 2011;8(1):27-31] (ISSN: 1097-8135).
- 出版日期2011
- 单位郑州大学
